Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 4
2009 1
2010 1
2011 3
2012 2
2013 4
2014 15
2015 22
2016 25
2017 11
2018 14
2019 10
2020 15
2021 15
2022 17
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Onychomycosis: Treatment and prevention of recurrence.
Lipner SR, Scher RK. Lipner SR, et al. J Am Acad Dermatol. 2019 Apr;80(4):853-867. doi: 10.1016/j.jaad.2018.05.1260. Epub 2018 Jun 28. J Am Acad Dermatol. 2019. PMID: 29959962 Review.
Onychomycosis: a review.
Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Gupta AK, et al. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1972-1990. doi: 10.1111/jdv.16394. Epub 2020 Jun 5. J Eur Acad Dermatol Venereol. 2020. PMID: 32239567 Review.
Terbinafine, itraconazole and fluconazole are most commonly used, with new oral antifungals such as fosravuconazole being evaluated. Topical treatments, such as efinaconazole, tavaborole, ciclopirox and amorolfine have less serious side effects, but also have generally low …
Terbinafine, itraconazole and fluconazole are most commonly used, with new oral antifungals such as fosravuconazole being evaluated. Topical …
Updated Perspectives on the Diagnosis and Management of Onychomycosis.
Falotico JM, Lipner SR. Falotico JM, et al. Clin Cosmet Investig Dermatol. 2022 Sep 15;15:1933-1957. doi: 10.2147/CCID.S362635. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 36133401 Free PMC article. Review.
Oral terbinafine, itraconazole, and griseofulvin and topical ciclopirox 8% nail lacquer, efinaconazole 10% solution, and tavaborole 5% solution are approved by the Food and Drug Administration for treatment of onychomycosis in the United States and amorolfine 5% nail lacqu …
Oral terbinafine, itraconazole, and griseofulvin and topical ciclopirox 8% nail lacquer, efinaconazole 10% solution, and tavaborole 5 …
Efinaconazole and Tavaborole.
Poulakos M, Grace Y, Machin JD, Dorval E. Poulakos M, et al. J Pharm Pract. 2017 Apr;30(2):245-255. doi: 10.1177/0897190016630904. Epub 2016 Jul 8. J Pharm Pract. 2017. PMID: 26873506 Review.
PURPOSE: The purpose of this article is to review the safety, efficacy, and role of efinaconazole and tavaborole in the treatment of onychomycosis. SUMMARY: Onychomycosis is a fungal infection of the nail caused by dermatophytes, yeasts, and nondermatophyte fungi. ...The o …
PURPOSE: The purpose of this article is to review the safety, efficacy, and role of efinaconazole and tavaborole in the treatment of …
Tavaborole.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999785 Free Books & Documents. Review.
Topical tavaborole has not been studied during breastfeeding. Because blood levels are very low after topical application to the toenails, it is unlikely that a measurable amount of the drug will enter the breastmilk....
Topical tavaborole has not been studied during breastfeeding. Because blood levels are very low after topical application to the toen …
Novel and Investigational Treatments for Onychomycosis.
Gregoriou S, Kyriazopoulou M, Tsiogka A, Rigopoulos D. Gregoriou S, et al. J Fungi (Basel). 2022 Oct 14;8(10):1079. doi: 10.3390/jof8101079. J Fungi (Basel). 2022. PMID: 36294644 Free PMC article. Review.
The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment disease-free time and a lack of systemic impact on the patients' health. Efinaconazole, Tavaborole, and Luliconazole have been added to phy …
The development of new topical drugs for onychomycosis is driven by the unmet need for effective agents with prolonged post-treatment diseas …
5-Trifluoromethyl-2-formylphenylboronic Acid.
Adamczyk-Woźniak A, Gozdalik JT, Wieczorek D, Madura ID, Kaczorowska E, Brzezińska E, Sporzyński A, Lipok J. Adamczyk-Woźniak A, et al. Molecules. 2020 Feb 12;25(4):799. doi: 10.3390/molecules25040799. Molecules. 2020. PMID: 32059517 Free PMC article.
It showed possible binding of the cyclic isomer into the binding pocket of Candida albicans LeuRS, similar to that of the recently approved benzoxaborole antifungal drug (AN2690, Tavaborole, Kerydin). In case of Escherichia coli LeuRS, the opened isomer displays a much hig …
It showed possible binding of the cyclic isomer into the binding pocket of Candida albicans LeuRS, similar to that of the recently approved …
Treatment of onychomycosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Oct 18;63(1635):164-168. Med Lett Drugs Ther. 2021. PMID: 35050243 No abstract available.
Boron-Containing heterocycles as promising pharmacological agents.
Das BC, Adil Shareef M, Das S, Nandwana NK, Das Y, Saito M, Weiss LM. Das BC, et al. Bioorg Med Chem. 2022 Jun 1;63:116748. doi: 10.1016/j.bmc.2022.116748. Epub 2022 Apr 18. Bioorg Med Chem. 2022. PMID: 35453036 Review.
Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, and several other boron-containing compounds are in clinical trials. ...
Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, …
Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.
Zane LT, Plattner J, Chanda S, Coronado D, Merchant T, Alley MR, Gupta AK. Zane LT, et al. Drugs Today (Barc). 2015 Oct;51(10):599-607. doi: 10.1358/dot.2015.51.10.2401004. Drugs Today (Barc). 2015. PMID: 26583302 Review.
Tavaborole topical solution, 5% (tavaborole) is a novel, boron-based, antifungal pharmaceutical agent indicated for treatment of toenail onychomycosis due to the dermatophytes Trichophyton rubrum or Trichophyton mentagrophytes. ...Results from preclinical studies an
Tavaborole topical solution, 5% (tavaborole) is a novel, boron-based, antifungal pharmaceutical agent indicated for treatment
149 results